Pilot, Prospective, Comparative Multicentric Study Evaluating the Effects on the Arthrosis Biomarkers, the Clinical Effectiveness, the Tolerance of an Intra-articular Injection of Hyaluronic Acid KARTILAGE CROSS Versus Placebo in Patients Suffering From Knee Osteoarthritis
NCT ID: NCT02951585
Last Updated: 2016-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
81 participants
INTERVENTIONAL
2013-05-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The US food and drugs administration (FDA) and European medicine agency (EMA), have recently published guidelines recommending a higher level of integration of biomarkers in the development and testing of new drugs to advance decision-making on dosing, time and treatment effect, trial design, and risk/benefit analysis. Biomarkers can be used not only in the process of drug development, but also in the future in assessment of individual patient's response to treatment.
Several soluble biomarkers have been identified as potential candidates to predict or monitor the efficacy of intervention. Coll2-1, a degradation product of type II collagen, and Coll2-1NO2, a nitrated form of the Coll2-1 peptide have been studied in human osteoarthritis and entered the qualification process. Evidences demonstrated them to be pertinent and to be foresee as markers used for the diagnosis, the prognosis, the burden of disease and the monitoring of a treatment efficacy.
The aim of this study was to provide with the first kinetic data regarding biomarkers in painful knee osteoarthritis patients treated with a new reticulated hyaluronic acid. The effects of the treatment were compared to those of saline solution. The primary endpoint was a specific osteoarthritis biomarker, Coll2-1. The secondary endpoints were the effects of the treatment or placebo on other biomarkers of osteoarthritis, its clinical efficacy and tolerance
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KARTILAGE CROSS
Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
KARTILAGE CROSS
Intra-articular injection of Kartilage Cross
Placebo
Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
PLACEBO
Intra-articular injection of physiological serum (saline solution)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KARTILAGE CROSS
Intra-articular injection of Kartilage Cross
PLACEBO
Intra-articular injection of physiological serum (saline solution)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting a symptomatic femoro-tibial knee osteoarthritis responding to clinical and radiologic ACR (American College of Rheumatology) criteria,
* Symptomatic since at least 6 months
* Mean global knee pain determined on Visual Analog Scale for the last 24 hours over 40 mm (without any NSAIDs or analgesics for more than 48 hours).
* Kellgren and Lawrence (K\&L) radiological stage must have been II or III on pictures lasted less than 12 months
* Requiring a treatment with hyaluronic acid after failure or intolerance to first line analgesics or NSAIDs
* Having signed an informed consent after receiving comprehensive information
* Capable to follow the study instructions
* Benefiting from health insurance.
Exclusion Criteria
* Significant clinical knee effusion
* Radiographical Kellgren and Lawrence grade I or IV
* Osteoarthritis secondary to a microcrystalline arthropathy: chondrocalcinosis previously known or defined by a calcium border on at least one tibiofemoral spacing, gout ...
* Isolated femoropatellar osteoarthritis
* Presence of another joint (other than the evaluated knee) affected by osteoarthritis (known and symptomatic): collateral knee, hip, hand, shoulder, ankle or foot
* Chondromatosis or villonodular synovitis of the knee
* Paget disease
* Recent trauma (\< 1 month) of the evaluated knee
* Pathologies interfering with the evaluation of osteoarthritis (microcrystalline inflammatory arthropathy, rheumatoid arthritis, radiculalgia in the lower limbs, arteritis. etc)
* Acute inflammatory osteoarthritis (Kofus ≥ 7)
Related to previous and concomitant treatments
* Corticosteroids injection in the last month before injection regardless the concerned joint
* Hyaluronan injection in the last 6 months before injection regardless the concerned joint
* Analgesics and NSAIDs intake during the last 48 hours before inclusion visit
* Change in the dosage of slow-acting drugs against arthrosis i.e. chondroitin, glucosamine, diacerein or avocado-soybean unsaponifiables in the last 3 months before inclusion or planned during study
* Arthroscopy or surgery in the target knee in the last 3 months before inclusion
* Oral corticotherapy
Related to associated pathologies
* Severe diseases (severe hepatic failure, renal failure, uncontrolled cardiovascular diseases….)
* Dermatological infection at the site of injection
* Anticoagulant treatment
* Risk of hemorrhage according to the evaluator or injector assessment
Related to the patients
* Known allergy to hyaluronan
* Known allergy to acetaminophen
* Known allergy to mannitol
* Pregnant or breastfeeding women
* Premenopausal women without contraception
* Patient unable to read, and to write
* Patient having participated in a clinical research investigation in the last 3 months
* Patient under guardianship or judicial protection
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Artialis
INDUSTRY
Laboratoires Vivacy
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
References
Explore related publications, articles, or registry entries linked to this study.
Henrotin Y, Berenbaum F, Chevalier X, Marty M, Richette P, Rannou F. Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE(R) CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial. BMC Musculoskelet Disord. 2017 May 26;18(1):222. doi: 10.1186/s12891-017-1585-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-A01521-42
Identifier Type: -
Identifier Source: org_study_id